Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2020-01-07 Report Publication Anno…
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Revenue Guidance
Report Publication Announcement Classification · 1% confidence The document is very short (1950 chars) and explicitly states: "Attached hereto is a report on*Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Revenue Guidance* *\_2020\_Guidance\_\_FINAL\_isa.pdf*". This structure—an announcement referencing an attached or linked primary document (which contains preliminary revenue figures and guidance)—fits the definition of a Report Publication Announcement (RPA). It is not the full Earnings Release (ER) or Interim Report (IR), but the notice that those results/guidance documents are available. The filing is made to the Israel Securities Authority (ISA) and Tel Aviv Stock Exchange (TASE) under immediate report regulations.
2020-01-07 English
Immediate Report
AGM Information Classification · 1% confidence The document is explicitly titled 'FORM 6-K' and is a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934'. Form 6-K filings are used to report material information that a foreign private issuer is required to disclose to its home country regulators or stock exchange. The key content provided in Exhibit 99.1 is the 'Notice of Results of the 2019 Annual General Meeting of Shareholders'. Since the document reports the official results of shareholder votes from the AGM, it directly corresponds to the Declaration of Voting Results & Voting Rights Announcements category (DVA). Although it relates to an AGM, the core function of this specific filing is reporting the voting outcomes, not general AGM presentation materials (AGM-R).
2019-12-26 English
Immediate Report
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states 'Notice of Results of the 2019 Annual General Meeting of Shareholders, held on December 24, 2019'. This directly relates to the outcome of a shareholder vote following an AGM. The definition for Declaration of Voting Results & Voting Rights Announcements (DVA) is 'Official results from shareholder votes at any general meeting (AGM or EGM)'. Although the text mentions an attachment ('Attached hereto is a report on*Notice of Results...*'), the core subject matter is the voting results, making DVA the most specific classification over a general RPA or RNS. The document length is short (1885 chars), but the content is the result announcement itself, not just a notice that a result document exists.
2019-12-26 English
Immediate Report
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'FORM 6-K' and is a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934'. Form 6-K filings are used by foreign private issuers to report material information to the SEC, often including press releases or other material events not covered by the standard 10-K or 10-Q. The content attached is a press release announcing the enrollment of the first patient in a pivotal Phase 3 clinical trial. Since Form 6-K is a general regulatory filing for foreign issuers that doesn't fit the specific categories like 10-K (Annual Report) or IR (Interim Report), and it is a formal submission to the SEC, the most appropriate classification among the provided options is the general regulatory filing category, RNS (Regulatory Filings), as it represents a required submission to the SEC that isn't one of the other specific report types. It is not an Earnings Release (ER) as it discusses clinical trial progress, nor is it a specific report like AR or IR, but rather the filing vehicle containing the announcement.
2019-12-16 English
Immediate Report
Regulatory Filings Classification · 1% confidence The document is very short (2005 characters) and explicitly states it is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. Crucially, it says, 'Attached hereto is a report on *Kamada Announces Enrollment of First Patient...*' followed by a PDF filename. This structure indicates that the document itself is an announcement about the release of other information, not the detailed report itself. According to Rule 2 ('MENU VS MEAL' RULE), when a document announces that a report is attached or published, it should be classified as a Report Publication Announcement (RPA). It is not a standard 10-K, IR, or ER, but a notification of a specific update.
2019-12-16 English
Immediate Report
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'FORM 6-K' and is filed 'For the Month of December 2019' with the SEC. Form 6-K is the standard filing used by Foreign Private Issuers to report material information that is made public outside of the U.S. The content attached is a 'Press Release' announcing a new contract manufacturing agreement and expected revenue impact. While the content is an announcement, the primary document structure is the SEC Form 6-K wrapper. Since Form 6-K is a general regulatory filing for foreign issuers that doesn't map directly to 10-K, ER, or IR, it falls under the general regulatory filing category. Given the options, 'RNS' (Regulatory Filings) is the most appropriate catch-all for non-standard SEC forms like 6-K, especially when the attached exhibit is a press release, which is often filed via 6-K or RNS.
2019-12-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.